NetSuite vs Sage Intacct for Biotech Consulting Revenue

Before comparing platforms, list every active engagement and classify how each one recognizes revenue: time-and-materials billed monthly, a milestone tied to a regulatory event like an IND filing, or a grant with its own spending restrictions and reporting deadlines. These three types don't behave the same way in a general ledger, and a system that treats them identically will misstate revenue the first time a milestone slips.

This mapping exercise alone usually surfaces contracts that have been recognized incorrectly for months, since regulatory-event milestones are easy to book on an estimated timeline rather than the actual filing date.

Take your largest milestone-based contract and walk both platforms through it: what happens to recognized revenue when the underlying regulatory event moves by a quarter? NetSuite's revenue recognition engine can handle contingent, event-triggered milestones natively, adjusting the schedule automatically when a date changes rather than requiring a manual journal entry.

Sage Intacct's automated revenue recognition is strong for straightforward subscription or ratable schedules, but event-triggered milestones tied to an external regulatory timeline often need more manual intervention to reschedule correctly, which matters if your firm runs many milestone contracts at once.

A grant that restricts spending to specific cost categories needs its own tracking separate from client fee revenue, with reporting that can prove funds were spent as the grant terms required. Both platforms can tag grant transactions by fund and category through dimensions or classes, but the reporting output needs to match what your specific grantor requires, which varies by funder.

Pass-through lab costs, reagents, specialized equipment time, or third-party testing billed under a study, need to stay traceable to the specific study that incurred them, not blended into general overhead. This matters both for client billing accuracy and for demonstrating cost allocation if a grant is ever audited.

A small consultancy with a handful of time-and-materials clients and no grant funding can run on QuickBooks using project-level classes. Once milestone contracts and grant restrictions both enter the mix, the manual tracking required to keep them separate becomes a real monthly burden, and that's usually the point firms in this space start evaluating a heavier platform.

Ask each vendor to model your actual largest contract from signature through a milestone delay, then show the deferred revenue schedule adjusting automatically. Frank, MeetMyCFO's AI CFO, can help you build that test scenario from a real contract before the vendor call, so you're testing your own recognition logic rather than a generic subscription example.

Gross margin in scientific and technical consulting tends to run leaner than pure software services once specialized labor and pass-through lab costs are factored in, so benchmark your margin against your own cost structure rather than assuming a blended industry number applies cleanly¹.

Run this test before you commit to a platform:

1. Choose your largest milestone-based contract and give each vendor the terms exactly as signed.
2. Ask the vendor to model the contract from signature through the regulatory milestone.
3. Move the milestone by a quarter and watch whether the deferred revenue schedule adjusts automatically.
4. Check that grant-restricted funds stay separate from fee revenue while the contract is being modeled.
5. Compare how much manual work each platform needed to produce the result.

Receivables days matter more here than in many consulting categories, since milestone payments often lag the actual regulatory event by weeks while the firm has already incurred the cost of getting there². Confirm how each system ages a receivable that's tied to a milestone rather than an invoice date, since the two can diverge significantly on a delayed contract.

Reagents, specialized equipment rental, and third-party testing labs often get billed to the firm first and passed through to the client or the grant afterward, which means the firm's own payables days on those vendors directly affects its cash position while it waits to bill or draw down³.

A firm that lets those pass-through vendor bills sit unpaid too long risks losing preferred terms with specialized labs it depends on for every study, a relationship cost that's easy to overlook until a lab starts requiring prepayment. Dimensional reporting that ties each vendor bill to the study and cost category that incurred it makes this easier to monitor than a flat accounts payable aging report ever could.